The Impact of CAR T-Cell Therapy on Cancer Care



At the 2018 National Association of Specialty Pharmacy (NASP) Annual Meeting and Educational Conference, Cheryl Allen, BSPharm, MBA, Vice President of Industry Relations at Diplomat Pharmacy, discussed novel therapies in cancer care, including the emergence of CAR T-cell therapy as a groundbreaking oncology treatment.

Transcript

You know, when we look at very novel therapies, the CAR T therapy is just fascinating. When we think about the ability to engineer a living cell to combat the patient’s cancer, it’s groundbreaking. What we see now in CAR T, and we’re looking at cancer therapy, we’re going to see that go all throughout different disease states and really begin to drilldown into precision therapy. 




Most Popular

Related Articles

Clinical trial demonstrates adoptive T-cell therapy may be successful in treating progressive multifocal leukoencephalopathy.
California’s tobacco control programs have lowered lung cancer deaths 33% faster than the rest of the United States.
Top news of the day from across the health care landscape.
Company Profile >
Contributors >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$